Pluri (PLUR) Competitors $4.83 -0.18 (-3.59%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$5.39 +0.56 (+11.59%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. ACXP, SLS, BIOA, ENTA, BDTX, LXEO, GLSI, PBYI, ALEC, and CTNMShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Acurx Pharmaceuticals (ACXP), SELLAS Life Sciences Group (SLS), BioAge Labs (BIOA), Enanta Pharmaceuticals (ENTA), Black Diamond Therapeutics (BDTX), Lexeo Therapeutics (LXEO), Greenwich LifeSciences (GLSI), Puma Biotechnology (PBYI), Alector (ALEC), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Acurx Pharmaceuticals SELLAS Life Sciences Group BioAge Labs Enanta Pharmaceuticals Black Diamond Therapeutics Lexeo Therapeutics Greenwich LifeSciences Puma Biotechnology Alector Contineum Therapeutics Pluri (NASDAQ:PLUR) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Do insiders & institutionals believe in PLUR or ACXP? 16.6% of Pluri shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 25.9% of Pluri shares are held by company insiders. Comparatively, 26.0% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to PLUR or ACXP? In the previous week, Acurx Pharmaceuticals had 3 more articles in the media than Pluri. MarketBeat recorded 3 mentions for Acurx Pharmaceuticals and 0 mentions for Pluri. Pluri's average media sentiment score of 0.00 beat Acurx Pharmaceuticals' score of -0.27 indicating that Pluri is being referred to more favorably in the media. Company Overall Sentiment Pluri Neutral Acurx Pharmaceuticals Neutral Which has better earnings & valuation, PLUR or ACXP? Acurx Pharmaceuticals has lower revenue, but higher earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$1.03M36.77-$20.89M-$5.53-0.87Acurx PharmaceuticalsN/AN/A-$14.10M-$14.00-0.33 Do analysts rate PLUR or ACXP? Pluri currently has a consensus price target of $12.00, suggesting a potential upside of 148.45%. Acurx Pharmaceuticals has a consensus price target of $160.00, suggesting a potential upside of 3,340.86%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PLUR or ACXP more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,563.29%. Acurx Pharmaceuticals' return on equity of -526.78% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-2,563.29% -4,191.91% -85.40% Acurx Pharmaceuticals N/A -526.78%-223.78% Which has more volatility and risk, PLUR or ACXP? Pluri has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.27, indicating that its share price is 227% less volatile than the S&P 500. SummaryAcurx Pharmaceuticals beats Pluri on 7 of the 13 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.47M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-0.8717.9729.8925.14Price / Sales36.77262.52421.4486.79Price / CashN/A41.8335.9458.58Price / Book4.837.238.125.59Net Income-$20.89M-$54.43M$3.26B$265.48M7 Day Performance-6.40%0.22%0.69%1.22%1 Month Performance-13.13%5.59%2.48%0.39%1 Year Performance-8.52%9.98%27.93%23.47% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri2.0717 of 5 stars$4.83-3.6%$12.00+148.4%-13.4%$39.47M$1.03M-0.87150ACXPAcurx Pharmaceuticals2.1845 of 5 stars$5.22-10.8%$8.00+53.4%-88.1%$162.87MN/A-7.563Upcoming EarningsSLSSELLAS Life Sciences Group2.2437 of 5 stars$1.61+0.9%$7.00+336.1%+36.8%$160.15M$1M-4.2210Upcoming EarningsBIOABioAge LabsN/A$4.43+0.2%N/AN/A$158.82MN/A0.00N/AEarnings ReportENTAEnanta Pharmaceuticals3.7026 of 5 stars$7.41+4.3%$18.50+149.8%-43.5%$158.21M$67.64M-1.63160BDTXBlack Diamond Therapeutics2.6448 of 5 stars$2.77-2.3%$12.80+362.9%-50.0%$157.79MN/A46.2590News CoveragePositive NewsGap DownLXEOLexeo Therapeutics2.3618 of 5 stars$4.74-0.6%$17.17+262.2%-62.0%$157.37M$650K-1.4458Upcoming EarningsGLSIGreenwich LifeSciences1.214 of 5 stars$11.70-2.0%$39.00+233.3%-14.9%$156.43MN/A-9.293News CoverageUpcoming EarningsPBYIPuma Biotechnology3.8634 of 5 stars$3.14-1.4%$7.00+123.3%-11.8%$156.19M$230.50M4.09200News CoverageEarnings ReportALECAlector4.1653 of 5 stars$1.55-0.2%$4.17+169.3%-70.3%$155.48M$100.56M-1.23270News CoverageEarnings ReportCTNMContineum Therapeutics2.4425 of 5 stars$6.04+4.1%$22.50+272.5%-60.1%$153.90M$50M-3.0231Earnings ReportUpcoming Earnings Related Companies and Tools Related Companies Acurx Pharmaceuticals Competitors SELLAS Life Sciences Group Competitors BioAge Labs Competitors Enanta Pharmaceuticals Competitors Black Diamond Therapeutics Competitors Lexeo Therapeutics Competitors Greenwich LifeSciences Competitors Puma Biotechnology Competitors Alector Competitors Contineum Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
